Amyotrophic lateral sclerosis (ALS) is a rare, progressing disease in which motor neurons degenerate or die diminishing the signals that control muscle function.
Orion’s phase 3 REFALS trial evaluating the efficacy of oral levosimendan in treatment of ALS patients did not reach its pre-specified endpoints.
A Review article summarizing the Potential of Levosimendan in the Management of ALS: Overview of a Working Hypothesis
The Phase 2 clinical trial (LEVALS) show encouraging results: in 66 patients supine SVC was significantly higher after 14 days treatment on oral levosimendan compared to placebo.
The REFALS trial is studying the effects of oral levosimendan in patients with amyotrophic lateral sclerosis (ALS).
The beginning and progression of ALS symptoms vary between people. The treatment is planned by a multi-professional team in cooperation with the patient. The patients’ families need support as well.
